Cordis DX®

Cordis DX® is a clinically validated test with high sensitivity and specificity that analyzes all genes of the human genome in order to detect variants associated with inherited cardiovascular diseases, such as:

Arrhythmias
Cardiomyopathies ◊ (Hypertrophic Cardiomyopathy - HCM, Distense Cardiomyopathy - DCM, Restrictive Cardiomyopathy - RCM, LVNC)
Hyperlipidemias - Dyslipidemias, such as Familial Hypercholesterolemia
Aortic Disorders - Aortic Dissections
Pulmonary Arterial Hypertension
Congenital heart disease
Ehlers - Danlos syndrome
Marfan syndrome
Long-QT & Short QT Syndromes
Noonan syndrome
Brugada syndrome
Catecholaminergic Polymorphic Ventricular Tachycardia Syndrome - CPVT

Why Cordis DX® cardiovascular disease gene testing is important

CordisDX® genetic analyses offer the physician maximum differential diagnosis, with high sensitivity and specificity rates, saving valuable time and costs per patient case.

Diagnosis: Cordis DX® confirms the clinical diagnosis in a reliable and fast way and reduces the need for more invasive procedures. Accurate diagnosis of inherited cardiovascular diseases is now possible with the use of genetic analysis, which minimizes dilemmas regarding the management and prognosis of the disease and assists the physician in estimating the appropriate timing for surgery.
The contribution of the test is particularly important in the diagnosis of hereditary arrhythmogenic diseases (channelopathies) that carry a high risk of sudden cardiac death in the setting of a structurally normal heart (e.g. Long QT syndrome, Brugada syndrome, etc.).

Prognosis: By knowing exactly the gene mutations that are responsible for a patient’s disease, we can predict its progression, taking into account all the factors that concern the specific patient.

We can also identify relatives who carry the same mutation and are at increased risk of developing the same disease, so they can be managed appropriately. The test’s contribution is especially important in families that carry genes associated with sudden cardiac death.

Management: The proper management of the patient and his family is based on the correct diagnosis and prognosis of the disease, so that the doctor is oriented towards the most appropriate treatment and management.

Informs about the avoidance of certain medications
Guides lifestyle modifications to reduce the risk of cardiac events as much as possible
Assists in the decision for early surgery and placement of an implantable cardioverter-defibrillator (ICD) or pacemaker
Identifies appropriate testing intervals and potential interventions for family members at risk
Enables the possibility of future re-analysis of the data, in light of a new phenotype in the individual or family, or new gene–phenotype associations, without the need to repeat the test

Cordis DX® cardiovascular disease gene testing is performed on a blood sample (2 vials of blood with EDTA)

CORDIS DX®

The Cordis DX® test analyzes the coding regions of approximately 22,000 human genes, including those whose pathogenic variants are associated with all possible inherited cardiovascular diseases.

International Guidelines

» Recommended by the European Society of Cardiology and the European Respiratory Society for the diagnosis and management of pulmonary hypertension
» Recommended by the Heart Rhythm Society (HRS) and European Heart Rhythm
» Association (EHRA) for the diagnosis and management of channelopathies.
» Recommended by the American Association of Cardiologists for the diagnosis and management of arrhythmias.
» Recommended by the Heart Failure Society of America and the European Society of Cardiology for the diagnosis and management of cardiomyopathy.

Frequently Asked Questions

Why should I choose the multi-gene test?: A multi-gene test increases the chances of finding a pathogenic variant over a single-gene one. Multi-gene tests confirm the diagnosis and enable the doctor to choose the most appropriate treatment plan.
If a pathogenic mutation is found, do I need additional tests?: If a pathogenic mutation is detected you should consult your doctor.
In how many days will the results be available?: Results will be available in 15 business days.
What sample is required for the test?: The test is performed on 2 vials of blood with EDTA. Blood collection can be done in any microbiological laboratory.
Is the test covered by any public/private insurance?: The test is not covered by public insurance. To find out more about possible private coverage you should contact your insurance company.
How do I make the payment for the test?: Payment can be made by bank transfer or debit/credit card.
How can I send my sample?: For the necessary sample collection procedures, please contact us at +30 210 6032138 .
Why should I sign the consent form?: For the use of the patient’s genetic material for testing, ELOT EN ISO9001:2008 and ELOT EN ISO15189:2012 require the written consent of each patient.
How will I receive my results?: Your results are shared with your GP via email.

How to order the test?

Our Customer Service Team is committed to answer your questions with regards to the services offered by Genekor. If you would like to order any of the tests that Genekor performs please contact us directly.

*To complete the test, you are required to complete and send the Consent form that you will find on the link below.